Cargando…

Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression

Multiple myeloma remains a largely incurable disease of clonally expanding malignant plasma cells. The bone marrow microenvironment harbors treatment-resistant myeloma cells, which eventually lead to disease relapse in patients. In the bone marrow, CD4(+)FoxP3(+) regulatory T cells (Tregs) are highl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dahlhoff, Julia, Manz, Hannah, Steinfatt, Tim, Delgado-Tascon, Julia, Seebacher, Elena, Schneider, Theresa, Wilnit, Amy, Mokhtari, Zeinab, Tabares, Paula, Böckle, David, Rasche, Leo, Martin Kortüm, K., Lutz, Manfred B., Einsele, Hermann, Brandl, Andreas, Beilhack, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885410/ https://www.ncbi.nlm.nih.gov/pubmed/34584204 http://dx.doi.org/10.1038/s41375-021-01422-y

Ejemplares similares

PB1980: MULTIPLE MYELOMA: ADOPTING MRD BY NEXT GENERATION FLOW CYTOMETRY (NGF) AND FUNCTIONAL IMAGING GUIDED CONSOLIDATION INTO CLINICAL ROUTINE
por: Boeckle, D., et al.
Publicado: (2022)

Junctional adhesion molecule C expression specifies a CD138(low/neg) multiple myeloma cell population in mice and humans
por: Brandl, Andreas, et al.
Publicado: (2022)

BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice
por: Zhou, Xiang, et al.
Publicado: (2022)

High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment
por: Solimando, Antonio Giovanni, et al.
Publicado: (2019)

Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease
por: Zhou, Xiang, et al.
Publicado: (2020)

18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical Features
por: Zhou, Xiang, et al.
Publicado: (2020)

A TNFR2-Specific TNF Fusion Protein With Improved In Vivo Activity
por: Vargas, Juan Gamboa, et al.
Publicado: (2022)

Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
por: Zhou, Xiang, et al.
Publicado: (2020)

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
por: Steinhardt, Maximilian Johannes, et al.
Publicado: (2020)

The Link between Cytogenetics/Genomics and Imaging Patterns of Relapse and Progression in Patients with Relapsed/Refractory Multiple Myeloma: A Pilot Study Utilizing 18F-FDG PET/CT
por: Zhou, Xiang, et al.
Publicado: (2020)

P836: ANTIBODY-DRUG CONJUGATES AS POTENTIAL CAR-T CELL SPECIFIC OFF-SWITCH IN MULTIPLE MYELOMA
por: Bielowski, Anna, et al.
Publicado: (2023)

COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from Würzburg and Wuhan
por: Zhou, Xiang, et al.
Publicado: (2020)

Dynamic Immune Cell Recruitment After Murine Pulmonary Aspergillus fumigatus Infection under Different Immunosuppressive Regimens
por: Kalleda, Natarajaswamy, et al.
Publicado: (2016)

Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression
por: Solimando, Antonio G., et al.
Publicado: (2020)

Exploration of Artificial Intelligence Use with ARIES in Multiple Myeloma Research
por: Loda, Sophia, et al.
Publicado: (2019)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
por: Zhou, Xiang, et al.
Publicado: (2020)

The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease
por: Dotterweich, Julia, et al.
Publicado: (2016)

Non-Invasive Imaging Provides Spatiotemporal Information on Disease Progression and Response to Therapy in a Murine Model of Multiple Myeloma
por: Riedel, Simone S., et al.
Publicado: (2012)

P814: ANALYSIS OF TP53 ALTERATIONS BY WGS REVEALS BIALLELIC 17P DELETIONS IN MULTIPLE MYELOMA
por: Truger, Marietta, et al.
Publicado: (2023)

A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials
por: Fleischer, Anna, et al.
Publicado: (2023)

JAM-A as a prognostic factor and new therapeutic target in multiple myeloma
por: Solimando, A G, et al.
Publicado: (2018)

The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma
por: Rasche, Leo, et al.
Publicado: (2019)

The Natural Human IgM Antibody PAT-SM6 Induces Apoptosis in Primary Human Multiple Myeloma Cells by Targeting Heat Shock Protein GRP78
por: Rasche, Leo, et al.
Publicado: (2013)

A T-Cell Surface Marker Panel Predicts Murine Acute Graft-Versus-Host Disease
por: Bäuerlein, Carina A., et al.
Publicado: (2021)

TNFRSF receptor-specific antibody fusion proteins with targeting controlled FcγR-independent agonistic activity
por: Medler, Juliane, et al.
Publicado: (2019)

Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma
por: Leipold, Alexander M., et al.
Publicado: (2023)

Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis
por: Kraus, Sabrina, et al.
Publicado: (2022)

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
por: Danhof, Sophia, et al.
Publicado: (2021)

Non-Invasive Bioluminescence Imaging to Monitor the Immunological Control of a Plasmablastic Lymphoma-Like B Cell Neoplasia after Hematopoietic Cell Transplantation
por: Chopra, Martin, et al.
Publicado: (2013)

Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab
por: Einsele, Hermann, et al.
Publicado: (2016)

Fibroblastic reticular cells mitigate acute GvHD via MHCII-dependent maintenance of regulatory T cells
por: Shaikh, Haroon, et al.
Publicado: (2022)

CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma
por: Lapa, Constantin, et al.
Publicado: (2017)

RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS
por: Seibold, Marcel, et al.
Publicado: (2019)

(11)C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions
por: Lapa, Constantin, et al.
Publicado: (2017)

Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma
por: Zhou, Xiang, et al.
Publicado: (2020)

The influence of baseline characteristics, treatment and depression on health-related quality of life in patients with multiple myeloma: a prospective observational study
por: Fischer, Julia, et al.
Publicado: (2022)

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells
por: García-Guerrero, Estefanía, et al.
Publicado: (2022)

Photoconversion of Alloreactive T Cells in Murine Peyer’s Patches During Acute Graft-Versus-Host Disease: Tracking the Homing Route of Highly Proliferative Cells In Vivo
por: Jarick, Katja J., et al.
Publicado: (2018)

Cytotoxic effects and tolerability of gemcitabine and axitinib in a xenograft model for c-myc amplified medulloblastoma
por: Schwinn, Stefanie, et al.
Publicado: (2021)

Three-Dimensional Light Sheet Fluorescence Microscopy of Lungs To Dissect Local Host Immune-Aspergillus fumigatus Interactions
por: Amich, Jorge, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_euighac8144ib35lcpjdh9bqq1